Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a global medical technology company whose news flow reflects its activity across anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. Company announcements frequently highlight portfolio developments, clinical research, financial performance, and governance changes, giving investors and healthcare professionals insight into how the business is evolving.
Recent Teleflex news has included leadership transitions, with the Board appointing a long-serving director as Interim President and Chief Executive Officer and naming a new Chair of the Board, as well as updates on the search for a permanent CEO. The company has also reported on strategic portfolio actions, such as agreements to sell its Original Equipment Manufacturing and Development Services business and its acute care and interventional urology segments, reflecting a shift toward a more focused organization centered on core critical care and high-acuity hospital markets.
On the operational side, Teleflex regularly issues quarterly earnings releases and outlook updates, detailing revenue by region and global product category, along with commentary on non-GAAP measures like adjusted revenue and adjusted constant currency revenue growth. Dividend declarations and share repurchase authorizations are also communicated through press releases and associated SEC filings.
For those following clinical and product developments, Teleflex news covers topics such as the launch of the Barrigel™ rectal spacer in new markets and support for investigator-initiated trials like the DUBSTENT DIABETES study in interventional cardiology. Visitors to this TFX news page can review these updates in one place to understand how Teleflex’s strategy, portfolio, and financial profile are changing over time.
Teleflex (NYSE:TFX) has announced its latest quarterly dividend. The company's Board of Directors has declared a cash dividend of $0.34 per share of common stock. The dividend will be paid on September 15, 2025, to shareholders who are on record as of August 15, 2025.
Teleflex (NYSE:TFX) reported strong Q2 2025 financial results, with GAAP revenue reaching $780.9 million, up 4.2% year-over-year, and adjusted constant currency growth of 1.0%. The company achieved GAAP diluted EPS from continuing operations of $2.77 and adjusted diluted EPS of $3.73.
Following the successful acquisition of BIOTRONIK's Vascular Intervention business, Teleflex raised its 2025 guidance, now expecting GAAP revenue growth of 9.00% to 10.00% and adjusted constant currency revenue growth of 7.70% to 8.70%. The company also increased its adjusted diluted EPS guidance to $13.90-$14.30.
By segment, Americas revenue grew 1.9%, EMEA increased 13.0%, and Asia rose 2.3% in Q2. The Interventional category showed the strongest performance with 20.4% growth, while OEM and Interventional Urology experienced declines of 11.4% and 8.1% respectively.
Teleflex (NYSE:TFX) has scheduled its second quarter 2025 earnings conference call for Thursday, July 31, 2025, at 8:00 a.m. Eastern Time. The company will discuss financial results and provide an operational update during the call.
Investors can access the call through pre-registration or via a live audio webcast on teleflex.com. An audio replay will be available from 11:00 am ET on the same day, accessible through the company website or by phone using the conference ID 69028.
Teleflex (NYSE:TFX) has completed its acquisition of BIOTRONIK's Vascular Intervention business for €760 million in cash. The acquisition significantly enhances Teleflex's global presence in the catheterization laboratory and establishes its footprint in the growing peripheral intervention market.
The acquired portfolio includes key products for coronary and peripheral interventions such as the Pantera Lux Drug-Coated Balloon Catheter, PK Papyrus Covered Coronary Stent, and Orsiro Mission Drug Eluting Stent. The deal also includes Freesolve, a CE-marked sirolimus-eluting Resorbable Metallic Scaffold technology.
Financially, the acquired products are expected to generate €177 million ($204 million) in revenues for the second half of 2025, with €91 million ($105 million) projected for Q4 2025. From 2026, the business is anticipated to deliver annual constant currency revenue growth of 6% or better. The transaction is expected to be $0.10 accretive to Teleflex's adjusted earnings per share in the first year.
Teleflex (NYSE: TFX) has released its 2024 Global Impact Report, detailing the company's Corporate Social Responsibility (CSR) achievements and future objectives. The report adheres to GRI, SASB, and TCFD standards, focusing on four key pillars: Community & Sustainable Healthcare, Planet & Environment, People, and Ethics & Governance.
Key highlights include: completion of a double materiality assessment aligned with E.U. Corporate Sustainability Reporting Directive, signing the World Economic Forum Zero Health Gaps Pledge for equitable healthcare access, submission of CDP Climate Questionnaire tracking greenhouse gas emissions since 2019, and maintaining ISO 14001 certification across 6 facilities.
Teleflex (NYSE:TFX) has announced a quarterly cash dividend of $0.34 per share of common stock. The dividend will be paid on June 16, 2025, to shareholders who are on record as of the close of business on May 20, 2025. This dividend declaration demonstrates the company's commitment to returning value to shareholders through regular cash distributions.